Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready
Yichang Humanwell Pharmaceutical Co. Ltd. has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners and 5 distinct art units. This distribution shows that the company's current patent applications are being reviewed by a range of individuals across several different technical groups.
JEFFREY T PALENIK is the busiest examiner, with 1 pending office action. With 6 pending office actions and 6 distinct examiners, the workload is spread such that each examiner is responsible for exactly one case. This lack of concentration means that no single examiner's habits will dominate the company's prosecution experience. The 5 distinct art units involved suggest that the 6 pending office actions cover a spectrum of pharmaceutical or biotechnological topics.
Practitioners should note that the 6 distinct examiners are operating in 5 distinct art units, meaning there is very little overlap in supervision for these cases. The busiest examiner, JEFFREY T PALENIK, manages 1 pending office action, which is consistent with the other examiners. This decentralized approach requires managing different examiner relationships across the 5 distinct art units to successfully prosecute the 6 pending office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 2 (33%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 1 | 53.6% | +27.2% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 46.9% | +81.0% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
| KETCHAM, KAREN A | 1 | 20.0% | +38.8% |
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
| ROSSI, JULIA ANNE LORRAIN | 1 | 45.7% | +61.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18387694 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS AND THEIR APPLICATIONS | AULAKH, CHARANJIT | 22d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293750 | DEXMEDETOMIDINE TRANSDERMAL COMPOSITION, TRANSDERMAL PATCH AND PREPARATION METHOD THEREFOR AND USE THEREOF | KETCHAM, KAREN A | 4d overdue |
| 18859689 | R-KETAMINE LIQUID PREPARATION AND USE THEREOF | PALENIK, JEFFREY T | — |
| 18605398 | SIGMA-1 RECEPTOR ANTAGONISTS AND THEIR APPLICATIONS | ROZOF, TIMOTHY R | — |
| 17404358 | LONG ACTING IN-SITU FORMING/GELLING COMPOSITIONS | ROSSI, JULIA ANNE LORRAIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293750 | DEXMEDETOMIDINE TRANSDERMAL COMPOSITION, TRANSDERMAL PATCH AND PREPARATION METHOD THEREFOR AND USE THEREOF | KETCHAM, KAREN A | 4d overdue |
| 18859689 | R-KETAMINE LIQUID PREPARATION AND USE THEREOF | PALENIK, JEFFREY T | — |
| 18633016 | MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS FOR THE TREATMENT OF PAIN AND RELATED MEDICAL DISORDERS | JOHNSON, CHRISTOPHER LINDSAY | — |
| 18605398 | SIGMA-1 RECEPTOR ANTAGONISTS AND THEIR APPLICATIONS | ROZOF, TIMOTHY R | — |
| 17404358 | LONG ACTING IN-SITU FORMING/GELLING COMPOSITIONS | ROSSI, JULIA ANNE LORRAIN | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1625 | 1 |
| 1614 | 1 |
| 1621 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18859689 | R-KETAMINE LIQUID PREPARATION AND USE THEREOF | PALENIK, JEFFREY T | — | §103§112 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18633016 | MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS FOR THE TREATMENT OF PAIN AND RELATED MEDICAL DISORDERS | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §112 | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18605398 | SIGMA-1 RECEPTOR ANTAGONISTS AND THEIR APPLICATIONS | ROZOF, TIMOTHY R | 1625 | §102§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18293750 | DEXMEDETOMIDINE TRANSDERMAL COMPOSITION, TRANSDERMAL PATCH AND PREPARATION METHOD THEREFOR AND USE THEREOF | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | 4d overdue | Pending | Jan 30, 2024 |
| 18387694 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS AND THEIR APPLICATIONS | AULAKH, CHARANJIT | 1621 | §112 | Non-Final OA | 22d | Pending | Nov 07, 2023 |
| 17404358 | LONG ACTING IN-SITU FORMING/GELLING COMPOSITIONS | ROSSI, JULIA ANNE LORRAIN | 1615 | §103§112 | Non-Final OA | — | Pending | Aug 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial